Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

NCT01728025 is registered in ClinicalTrials.gov with Tel-Aviv Sourasky Medical Center as lead sponsor.

NCT NCT01728025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01728025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine
Lead sponsor
Tel-Aviv Sourasky Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
October 31, 2012
Completion date
November 30, 2017
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

long qt syndrome type 3